Insider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Sells $942,637.50 in Stock

Key Points

• Elizabeth Lin sold 10,773 Tarsus Pharmaceuticals shares at an average price of $87.50, generating $942,637.50. The Rule 10b5-1 transaction reduced her direct holdings by 80.88%, leaving her with 2,547 shares.
• TARS shares fell 5.1% to $82.77, though they remained near their 52-week high of $91.53. The company recently reported a quarterly loss of $0.43 per share, missing estimates, despite revenue exceeding expectations.
• Institutional investors own approximately 90.01% of the stock, while analysts maintain a consensus “Moderate Buy” rating with an average price target of $92.57.

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) insider Elizabeth Lin sold 10,773 shares of the firm's stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $87.50, for a total transaction of $942,637.50. Following the sale, the insider directly owned 2,547 shares of the company's stock, valued at approximately $222,862.50. This trade represents a 80.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Elizabeth Yeu Lin also recently made the following trade(s):

• On Friday, September 4th, Elizabeth Lin sold 3,180 shares of Tarsus Pharmaceuticals stock. The shares were sold at an average price of $87.50, for a total transaction of $278,250.00.
• On Wednesday, September 2nd, Elizabeth Lin sold 1,590 shares of Tarsus Pharmaceuticals stock. The shares were sold at an average price of $80.00, for a total transaction of $127,200.00.
• On Wednesday, September 2nd, Elizabeth Lin sold 5,387 shares of Tarsus Pharmaceuticals stock. The stock was sold at an average price of $80.00, for a total transaction of $430,960.00.
• On Tuesday, September 1st, Elizabeth Lin sold 4,601 shares of Tarsus Pharmaceuticals stock. The stock was sold at an average price of $73.86, for a total transaction of $339,829.86.

Tarsus Pharmaceuticals Stock Down 5.1%

TARS traded down $4.45 during midday trading on Wednesday, hitting $82.77. The company had a trading volume of 556,805 shares, compared to its average volume of 755,010. The stock's 50 day moving average price is $67.09 and its 200 day moving average price is $66.33. Tarsus Pharmaceuticals, Inc. has a 52 week low of $48.20 and a 52 week high of $91.53. The company has a market capitalization of $3.63 billion, a price-to-earnings ratio of -75.94 and a beta of 0.54. The company has a quick ratio of 3.17, a current ratio of 3.20 and a debt-to-equity ratio of 0.21.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.24). Tarsus Pharmaceuticals had a negative return on equity of 13.53% and a negative net margin of 7.67%.The company had revenue of $173.91 million for the quarter, compared to the consensus estimate of $169.65 million. On average, research analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -2.4 earnings per share for the current fiscal year.

Institutional Trading of Tarsus Pharmaceuticals

Several institutional investors have recently made changes to their positions in TARS. BlackRock Inc. bought a new position in shares of Tarsus Pharmaceuticals during the second quarter valued at about $242,705,000. Jupiter Topco LLC bought a new stake in Tarsus Pharmaceuticals in the 2nd quarter worth about $176,834,000. California State Teachers Retirement System increased its stake in Tarsus Pharmaceuticals by 5,971.9% in the 2nd quarter. California State Teachers Retirement System now owns 2,288,813 shares of the company's stock valued at $144,058,000 after buying an additional 2,251,118 shares during the last quarter. Deep Track Capital LP increased its stake in Tarsus Pharmaceuticals by 71.4% in the 3rd quarter. Deep Track Capital LP now owns 3,000,000 shares of the company's stock valued at $178,290,000 after buying an additional 1,250,000 shares during the last quarter. Finally, Bank of America Corp DE bought a new position in shares of Tarsus Pharmaceuticals during the 2nd quarter worth approximately $75,099,000. Institutional investors own 90.01% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on TARS shares. Guggenheim lowered their target price on Tarsus Pharmaceuticals from $90.00 to $89.00 and set a "buy" rating on the stock in a research report on Tuesday, July 21st. Oppenheimer raised their price objective on shares of Tarsus Pharmaceuticals from $97.00 to $100.00 and gave the company an "outperform" rating in a research note on Wednesday, August 12th. Mizuho reduced their price objective on shares of Tarsus Pharmaceuticals from $100.00 to $98.00 and set an "outperform" rating for the company in a report on Friday, July 31st. Weiss Ratings reissued a "sell (d-)" rating on shares of Tarsus Pharmaceuticals in a research report on Friday, July 17th. Finally, Jefferies Financial Group upped their target price on shares of Tarsus Pharmaceuticals from $88.00 to $105.00 and gave the stock a "buy" rating in a report on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Tarsus Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $92.57.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company's research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus's lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.